PRESS RELEASE – Crassula Pharmaceuticals

Q-NiFlex™ and Phytosome Quantum Nano Sphere (PQNS™) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management

Erwin De La Rosa — Thu, 16 Jul 2026 21:58:41 +0000

Q-NiFlex and Phytosome Quantum Nano Sphere (PQNS) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management

Issue - 07 |
July - 2026 |
PRINT ISSN No. 2277 - 8179

Published review outlines the multi-target formulation and nano-delivery mechanism; a 500-patient randomized controlled trial is underway to evaluate clinical outcomes

A peer-reviewed paper published in the International Journal of Scientific Research (Vol. 15, Issue 7, July 2026; DOI: 10.36106/ijsr) outlines the scientific rationale behind Q-NiFlex^TM, a multi-component nutraceutical for joint health, and its proprietary Phytosome Quantum Nano Sphere (PQNS) delivery technology.

The paper, authored by Dr. Pallavi Singh (BDS, MDS, Government Hospital, Indore, M.P.) and Dr. Raj Bhan Singh (MD Anesthesiology, Assistant Professor, ESIC Medical College & Hospital, Indore, M.P.), reviews how PQNS combines phytosome complexation with nano-sized vesicular delivery — an approach intended to improve the stability, gastrointestinal protection, and systemic bioavailability of phytoconstituents that are otherwise poorly absorbed, such as curcumin and other botanical extracts.

Q-NiFlex^TM combines glucosamine sulphate, chondroitin sulphate, hyaluronic acid, Boswellia serrata, Curcuma longa, Cissus quadrangularis, and a range of complementary botanicals, amino acids, vitamins, and minerals in a once-daily tablet, formulated to address five functional domains relevant to osteoarthritis: structural cartilage support, inflammation modulation, oxidative stress reduction, connective tissue regeneration, and delivery optimization.

“Osteoarthritis is a multifactorial condition, and single-ingredient supplements have struggled to address that complexity,” the authors note in the paper. “Q-NiFlex^TM was developed on a multi-target philosophy, and PQNS is the delivery system intended to make that formulation more bioavailable.”

Clinical study underway

The paper is explicit that mechanistic rationale is not the same as clinical proof. A prospective, randomized, placebo-controlled study is currently underway to evaluate the efficacy and safety of Q-NiFlex^TM in approximately 500 osteoarthritis patients, with a 12-week treatment period and follow-up to 16 weeks. Primary endpoints include change in WOMAC score from baseline; secondary endpoints include VAS pain scores, physician global assessment, and safety labs.

“Independent, peer-reviewed clinical trial results will be essential to validate the proposed advantages of PQNS technology,” the authors write. No efficacy claims are made pending that trial’s results.

About the PQNS platform

PQNS is a phytosome- and nano-vesicular delivery platform developed by Integria Care, designed to improve the absorption and stability of poorly bioavailable actives.

Source: News By Wire
https://newsbywire.com/eer-reviewed-paper-details-phytosome-quantum-nano-sphere-pqns-delivery-platform-behind-q-niflex-joint-health-nutraceutical/

The post Q-NiFlex™ and Phytosome Quantum Nano Sphere (PQNS™) Technology: A Next-Generation Multi-Target Drug Delivery Strategy for Joint Health and Osteoarthritis Management appeared first on Crassula Pharmaceuticals.

Crassula Launches Q-Niflex™ — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere™ Delivery Platform

admin — Mon, 22 Dec 2025 02:05:27 +0000

Crassula Launches Q-Niflex — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere Delivery Platform

Indore, India — Crassula LLC has launched Q-Niflex, a dietary supplement engineered for joint comfort, mobility, and cartilage support. Introduced at an event in Indore, Q-Niflex is the first finished consumer product to bring Integria Care’s QuanticSphere delivery platform to the Indian supplement market, pairing a Crassula-developed formulation with Integria Care’s PQNS delivery technology.

The launch reflects a two-part model behind the product. Integria Care supplies the delivery science — the QuanticSphere platform and its PQNS technology. Crassula LLC developed the finished blend and manufactures the consumer dosage form. Q-Niflex is where the two meet: an Integria Care delivery architecture inside a Crassula-formulated joint-health supplement.

The Architecture Behind Q-Niflex

QuanticSphere is Integria Care’s human-health delivery platform, and its core technology is PQNS (Phytosome Quantum Nano Sphere) — a cationic phospholipid vesicular delivery system (Patent Pending 202521095813). PQNS engineers bioactives into nano-scale phospholipid vesicles, 100–200 nm in size, designed to shield sensitive compounds from degradation in the digestive tract and support efficient transport across biological membranes.

Q-Niflex maps that delivery architecture to a specific set of biological functions: joint comfort, mobility, and cartilage support. Rather than relying on higher doses to compensate for poor absorption, the formulation is engineered to deliver its bioactives more efficiently — the QuanticSphere approach of improving uptake at the point of delivery rather than simply increasing the amount taken.

Addressing the Absorption Challenge

Many joint- and wellness-oriented bioactives are poorly absorbed in conventional form, which can require larger doses to reach meaningful levels in the body. PQNS is designed to improve ingredient transport across biological membranes, maintain stability in the gastrointestinal environment, and support sustained availability — with attention to digestive comfort and everyday tolerability that supports long-term use.

The platform’s safety architecture is built in by design: lower effective loads, sustained rather than spiking availability, no synthetic bioenhancers (no piperine), and GRAS-status phospholipid and biopolymer carriers that are fully biodegradable.

Expert Perspectives at the Launch

Scientists from Integria Care, which developed the QuanticSphere platform, spoke to the delivery science inside Q-Niflex.

Dr. Bhawana Gupta, Chief Scientific Officer, Integria Care, described the mechanism:

“PQNS is engineered to protect bioactives and improve how efficiently they are delivered. By encapsulating ingredients in nano-scale, phospholipid-based vesicles, the technology maintains stability while supporting consistent uptake — the same delivery architecture now built into Q-Niflex.”

Dr. Lavleen Gupta, Executive Director, Science & Innovation, Integria Care, addressed the broader platform:

“QuanticSphere is a modular platform, not a single-product technology. Q-Niflex is one application, focused on joint and mobility support. The same Integria technology can be deployed across many nutritional categories as we continue to expand.”

Health and nutrition professionals attending the event noted the growing interest in better-absorbed, everyday joint-support nutrition and the role that delivery technology can play in it.

A Platform for Future Products

QuanticSphere is designed as a modular, scalable platform capable of supporting a wide range of bioactives — vitamins, minerals, botanical extracts, and other nutritional compounds. Integria Care continues to develop the platform and its technology library, while Crassula LLC plans to expand its QuanticSphere-powered product line across additional wellness categories, with Q-Niflex as the first entry.

With this launch, Integria Care’s delivery science and Crassula LLC’s formulation and manufacturing come together in a finished supplement built on a simple premise: better delivery, engineered by design — engineered by science, powered by PQNS.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

About Integria Care Integria Care develops the QuanticSphere delivery platform and the PQNS technology, supplying advanced delivery science and finished B2B blends to brand owners and manufacturers. www.integriacare.com · info@integriacare.com

About Crassula LLC Crassula LLC develops and manufactures finished consumer supplement formulations, including Q-Niflex, built on Integria Care’s QuanticSphere delivery technology.

The post Crassula Launches Q-Niflex™ — a Joint & Cartilage-Health Dietary Supplement Powered by Integria Care’s QuanticSphere™ Delivery Platform appeared first on Crassula Pharmaceuticals.

India Independence Day

admin — Thu, 15 Aug 2024 04:50:35 +0000

On this special day, we join in celebrating India’s 78th Independence Day, honoring the resilience, unity, and unwavering spirit of its people. As we commemorate the journey to freedom, let us continue striving for progress and prosperity. Wishing everyone a day filled with pride and reflection. Happy Independence Day!

The post India Independence Day appeared first on Crassula Pharmaceuticals.

We are proud to announce a new addition to our team at CRASSULA!

admin — Tue, 16 Apr 2024 20:16:43 +0000

We are proud to announce a new addition to our team at CRASSULA!

We are thrilled to announce an exciting new addition to our team at CRASSULA!

Please join us in welcoming Daniel Suazo as the new Medical Representative Lead at #CrassulaHonduras. Daniel comes to us with an impressive background in the healthcare sector, where he has consistently demonstrated exceptional leadership and a deep commitment to improving access to quality treatments.
In his new role, Daniel will play a crucial part in advancing our initiatives to enhance the accessibility and quality of life for patients in Honduras. We are confident that his expertise and leadership will greatly contribute to our efforts in delivering innovative and effective solutions to those in need.

Welcome aboard, Daniel! We are excited to see all the great things we will accomplish together.

#Welcome #PharmaceuticalIndustry #HealthInnovation #TeamCrassula #CrassulaHonduras

The post We are proud to announce a new addition to our team at CRASSULA! appeared first on Crassula Pharmaceuticals.

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

admin — Sun, 24 Mar 2024 17:25:54 +0000

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.

Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimize efficacy while minimizing potential side effects, ensuring a better quality of life for patients.

“Through the launch of Relixib, Crassula Honduras underscores its ongoing commitment to enhance healthcare outcomes with innovative and accessible treatment options. Relixib exemplifies our mission to address unmet medical needs in the management of pain and inflammation,” stated Dr. Bhawana Gupta, CTO of Crassula Pharmaceuticals. “We are proud to offer this significant advancement in pain management to the people of Honduras, furthering our goal of making superior healthcare solutions readily accessible.”

Relixib is now available in Honduras, offering a new hope for patients seeking effective management of chronic pain and inflammatory conditions. For more information about Relixib and other Crassula Pharmaceuticals products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Honduras

Crassula Honduras is a division of Crassula Pharmaceuticals, a company synonymous with high-quality healthcare products. With a focus on innovation, quality, and patient safety, Crassula strives to improve health and well-being in Honduras and beyond. The company’s diverse product portfolio meets a wide range of healthcare needs, ensuring that patients have access to the latest advancements in medical treatment.

The post Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras appeared first on Crassula Pharmaceuticals.

Dr. Bhavana Gupta

admin — Thu, 08 Feb 2024 22:07:27 +0000

Crassula Pharmaceuticals Welcomes

Crassula is thrilled to announce the appointment of Dr. Bhavana Gupta as its new Chief Technical Officer (CTO). Dr. Gupta will be at the forefront of managing the technical operations of the company, including overseeing the research and development department. Her role will also encompass serving as a vital technical advisor, directly reporting to Mr. Roopesh Gupta, the CEO and Founder of Crassula Pharmaceuticals.

Dr. Gupta brings to Crassula a rich background in medicine and biotechnology, holding a Ph.D. in Biotechnology. With over 17 years of research experience in Contract Research Organizations (CRO) and preclinical drug discovery within the pharmaceutical industry, Dr. Gupta’s expertise is a valuable addition to Crassula. She is renowned for her exceptional leadership in project management, customer communications, target identification and validation, and high-throughput screening (HTS).

An accomplished scientist, Dr. Gupta possesses profound knowledge in cell biology, assay development, and screening, particularly focusing on small molecules, biologics, and the discovery of natural product drugs. Her ability to skillfully balance organizational objectives with productivity and relationships has consistently enhanced competitive business edges in her previous roles.

Before joining Crassula, Dr. Gupta contributed significantly to the pharmaceutical and biotechnology fields through her roles as Assistant General Manager and Head of Cell Biology at Natco Pharmaceuticals, Senior Principal Scientist at Sapien Biosciences, and Team Lead at TCG Life Sciences. Her extensive experience spans various therapeutic areas, including pain, inflammation, immuno-oncology, and metabolic disorders, making her a pivotal figure in drug discovery.

Dr. Gupta’s appointment marks a significant milestone in Crassula’s journey towards innovation and excellence in pharmaceuticals. Her leadership and expertise are expected to drive forward the company’s mission of developing groundbreaking solutions for healthcare challenges.

About Crassula

Crassula LLC is a company dedicated to the production of pharmaceutical and nutraceutical solutions. Our presence extends internationally, manufacturing prescription drugs (Rx), nutritional supplements, and over-the-counter (OTC) pharmaceutical products. We strive to improve the health and well-being of communities through reliable, innovative, affordable, and high-quality solutions.

For further information, please contact:

Lauren Sacks
Human Resources Manager
lauren.sacks@crassulapharma.com

The post Dr. Bhavana Gupta appeared first on Crassula Pharmaceuticals.